AKT1 and cancer: Mutations in PI3K pathway including PI3K mutations, AKT mutations and amplification, or PTEN loss, are found to be concurrent with RAS mutations in human cancer, indicating that RAS activation may not be sufficient to fully activate PI3K signaling.